GINKGO BIOWORKS

Tom Knight — an MIT computer science professor — had a radical idea: biology could be programmed like software. In 2008, he and four of his MIT students (Jason Kelly, Reshma Shetty, Barry Canton, and Austin Che) founded Ginkgo Bioworks in Knight's lab.

Their vision: build an organism engineering platform that could be as reliable and scalable as a semiconductor foundry. Instead of TSMC manufacturing chips to spec, Ginkgo would manufacture organisms to spec.

They went through Y Combinator in 2014 — the first biotech company to do so — and used the Silicon Valley playbook to raise massive funding for a biology company.

Horizontal platform for cell programming — essentially a "foundry" that engineers biological organisms to produce custom molecules for customers across pharmaceuticals, agriculture, food, fragrances, and industrial chemicals. Instead of selling a product, Ginkgo sells engineering services: companies come with a molecule they need, and Ginkgo programs a microorganism to produce it.

Revenue comes from foundry fees, royalties on products made with engineered organisms, and equity stakes in customer companies.

Cell Programming Foundry (custom organism engineering), Enzyme Development, Pathway Engineering, Strain Optimization, Concentric by Ginkgo (biosecurity and pathogen monitoring), and a growing library of biological parts and processes that gets more valuable with each project.

Platform network effects. Every organism Ginkgo engineers adds to its proprietary codebase — a biological database that makes each subsequent project faster and cheaper.

The more customers use the foundry, the more data Ginkgo accumulates, creating a moat. Acquisitions of Zymergen (2022) added capabilities.

Expanding into biosecurity (pandemic detection) through the Concentric subsidiary diversifies revenue.

Revenue. Despite raising $2.8 billion and going public via SPAC in 2021, Ginkgo's revenue has grown slowly.

The cell programming platform is genuinely innovative, but converting R&D projects into revenue-generating products takes years. The stock has dropped over 90% from its SPAC peak as investors lost patience with the gap between the vision and the financial reality.

Critics call it "the most expensive science project in biotech."

Viking Global, Cascade Investment (Bill Gates), Baillie Gifford, ARK Invest, General Atlantic, and Y Combinator (Ginkgo was the first biotech in YC) were key backers.